New treatment modalities in NF-related neuroglial tumors
- PDF / 1,695,674 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 167 Views
ANNUAL ISSUE PAPER
New treatment modalities in NF-related neuroglial tumors Roger J. Packer 1,2,3
&
Gilbert Vezina 4
Received: 18 May 2020 / Accepted: 25 May 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract The management of low-grade gliomas (LGGs) and other neuroglial tumors in children with neurofibromatosis type 1 (NF1) has not changed over the past 2–3 decades. With the widespread utilization of chemotherapy for younger children with progressive LGGs, outcomes have been good for most patients who have required treatment. However, some may progress after the initiation of chemotherapy and others, although radiographically responding or with stable disease, may develop progressive neurologic and visual deterioration. Molecular-targeted therapy has become an option for patients who have progressed after receiving chemotherapy and the mTOR inhibitors and bevacizumab have already shown some degree of efficacy. However, the greatest impact has been the introduction of the MEK inhibitors. A variety of different MEK inhibitors are in clinical trials and have already demonstrated the ability to result in radiographic tumor shrinkage in the majority of children with NF1 and progressive LGGs. Because of this efficacy, the MEK inhibitors have moved rapidly from phase I studies to ongoing phase III studies comparing their benefit directly to that of chemotherapy. The long-term ability of these agents to not only control disease, but improve visual and/or neurological function, as well as their short- and long-term safety, are open questions that can only be answered by well-constructed prospective, often randomized, clinical trials. Keywords Neurofibromatosis type 1 . Low-grade glioma . Molecular-targeted therapy . MEK inhibitors . Bevacizumab
Introduction The treatment of childhood low-grade gliomas (LGGs) has been essentially unchanged over the past 25 years [1, 2]. After initial decisions concerning the need for treatment, therapy has conventionally consisted of attempts of gross total removal of the tumor, if considered feasible, and subsequent consideration of radiation or chemotherapy dependent on a variety of different factors including age of the child, extent of the lesion, and the risk of impeding neurologic or visual * Roger J. Packer [email protected] 1
Center for Neuroscience and Behavioral Medicine, Children’s National Hospital, 111 Michigan Ave, NW, Washington, DC 20010, USA
2
Gilbert Family Neurofibromatosis Institute, Children’s National Hospital, 111 Michigan Ave, NW, Washington, DC 20010, USA
3
Brain Tumor Institute, Children’s National Hospital, 111 Michigan Ave, NW, Washington, DC 20010, USA
4
Division of Radiology, Children’s National Hospital, 111 Michigan Ave, NW, Washington, DC 20010, USA
compromise. For many young children and increasingly for those who are older, especially pre-pubertal patients, chemotherapy has been increasingly utilized instead of radiation therapy in attempts to delay, and in many cases, obviate the need for radiotherapy [1,
Data Loading...
